Janux Therapeutics Q3 net loss narrows on lower R&D expenses
JANX•Janux Therapeutics reported a third-quarter net loss of $21.57 million, or $0.34 per share, as research and development and administrative expenses fell. Collaboration revenue was $9.29 million and declined year over year.
1. Quarterly results
Janux Therapeutics reported third-quarter collaboration revenue of $9.29 million, net loss of $21.57 million, operating expenses of $40.55 million and operating loss of $31.26 million. Net loss narrowed from a year earlier as research and development and general and administrative expenses decreased.
2. Clinical program outlook
The first patient was dosed in a Phase 1 combination study of JANX013 and JANX007. The company expects to present initial clinical data from its JANX011 Phase 1 study on Nov. 9, 2026, and additional JANX007 Phase 1b data in the first half of 2027. Its JANX014 Phase 1 study continues to enroll patients with mCRPC.
